Developing mRNA vaccines to protect against tick-borne viruses
mRNA-Based Vaccines Against Tick Borne Thogotoviruses
This study is testing a new mRNA vaccine designed to protect against the Bourbon virus, which is spread by ticks, and aims to find the best way to help people stay safe from various tick-borne diseases.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11139160 on NIH RePORTER |
What this research studies
This research focuses on creating an mRNA vaccine specifically targeting the Bourbon virus, a tick-borne pathogen that poses significant health risks to humans. The approach involves testing the vaccine's effectiveness in a mouse model to understand how it works and to identify the best viral antigens for broader protection against various tick-borne viruses. By evaluating different combinations of antigens, the research aims to lay the groundwork for a universal vaccine that could protect against multiple tick-borne diseases. This innovative strategy addresses the growing threat of tick-borne illnesses exacerbated by climate change and other factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in areas where tick-borne diseases are prevalent or those who are at high risk of tick exposure.
Not a fit: Patients who do not live in tick-endemic areas or who are not at risk of tick exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce the incidence of tick-borne diseases in humans.
How similar studies have performed: While mRNA vaccines have shown success in other viral diseases, this specific approach targeting tick-borne pathogens is relatively novel and untested.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Boon, Adrianus Cm — Washington University
- Study coordinator: Boon, Adrianus Cm
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.